The compound you described, **1-(3,4-dihydroxyphenyl)-2-[[5-(2-methoxyphenyl)-4-prop-2-enyl-1,2,4-triazol-3-yl]thio]ethanone**, is a complex organic molecule with a specific structure. It is not widely known or researched in the scientific community, and its exact properties and applications are not well-documented.
**Here's why it's difficult to determine its importance for research:**
* **Lack of Information:** There's little to no publicly available information on this specific compound. It's possible it was synthesized for a specific research project or patent, but it hasn't been widely published or studied.
* **Complex Structure:** The structure of the compound suggests it might have biological activity, but without further research, it's hard to say what that activity might be. It contains multiple functional groups (hydroxyl, methoxy, triazole, etc.) that can interact with biological systems.
* **Unknown Applications:** Without information on its properties and biological activity, it's impossible to speculate on potential applications. It might be a potential drug candidate, a chemical reagent, or have other uses.
**To learn more about this compound, you could:**
* **Search for publications:** Try searching scientific databases like PubMed, Scopus, and Google Scholar using the compound's name or its structural features.
* **Contact experts:** If you know researchers working in organic chemistry, medicinal chemistry, or related fields, they might have information or insights about the compound.
* **Analyze the structure:** Using a chemical structure drawing program and knowledge of chemical principles, you could potentially make educated guesses about the compound's properties and potential applications.
Remember, research is an ongoing process, and new discoveries happen all the time. If the compound you're interested in is truly unique, it might take some time for its significance to be fully understood and explored.
| ID Source | ID |
|---|---|
| PubMed CID | 665093 |
| CHEMBL ID | 1323944 |
| CHEBI ID | 92388 |
| SCHEMBL ID | 13856524 |
| Synonym |
|---|
| smr000038039 |
| MLS000080519 , |
| ml085 |
| MLS-0014097.0001 |
| MLS-0014097.0002 |
| MLS002415565 |
| 1-(3,4-dihydroxyphenyl)-2-[[5-(2-methoxyphenyl)-4-prop-2-enyl-1,2,4-triazol-3-yl]sulfanyl]ethanone |
| 1-(3,4-dihydroxyphenyl)-2-{[5-(2-methoxyphenyl)-4-(prop-2-en-1-yl)-4h-1,2,4-triazol-3-yl]sulfanyl}ethanone |
| STL055608 |
| HMS2204N10 |
| AKOS005708543 |
| HMS3335C20 |
| CHEMBL1323944 |
| 1-(3,4-dihydroxyphenyl)-2-[[5-(2-methoxyphenyl)-4-prop-2-enyl-1,2,4-triazol-3-yl]thio]ethanone |
| cid_665093 |
| bdbm34274 |
| 1-[3,4-bis(oxidanyl)phenyl]-2-[[5-(2-methoxyphenyl)-4-prop-2-enyl-1,2,4-triazol-3-yl]sulfanyl]ethanone |
| 2-[[4-allyl-5-(2-methoxyphenyl)-1,2,4-triazol-3-yl]thio]-1-(3,4-dihydroxyphenyl)ethanone |
| SCHEMBL13856524 |
| CHEBI:92388 |
| Q27164126 |
| Class | Description |
|---|---|
| aromatic ketone | A ketone in which the carbonyl group is attached to an aromatic ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 6.0337 | 0.1409 | 11.1940 | 39.8107 | AID2451; AID2785 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 35.4813 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 10.0000 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 17.7828 | 0.1259 | 19.1169 | 125.8920 | AID2549 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 10.0000 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 15.8489 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| WRN | Homo sapiens (human) | Potency | 13.5771 | 0.1683 | 31.2583 | 100.0000 | AID651768; AID720497 |
| TDP1 protein | Homo sapiens (human) | Potency | 21.8528 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 19.9526 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 31.6228 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 50.1187 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 5.0119 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 12.1031 | 0.5406 | 17.6392 | 96.1227 | AID720503 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 17.6470 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 19.9526 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 50.1187 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 8.9125 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 8.9125 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 8.9125 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| geminin | Homo sapiens (human) | Potency | 16.3601 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 56.2341 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 28.1838 | 1.9953 | 25.5327 | 50.1187 | AID624288 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproprotein | Homo sapiens (human) | IC50 (µMol) | 72.4000 | 0.1250 | 16.2603 | 74.8000 | AID1056 |
| alkaline phosphatase, germ cell type preproprotein | Homo sapiens (human) | IC50 (µMol) | 6.7780 | 0.1100 | 11.3862 | 67.2000 | AID1017; AID1512; AID690 |
| nuclear receptor subfamily 4 group A member 1 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 14.8560 | 25.3537 | 34.6240 | AID748 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 13.4750 | 0.0005 | 3.3142 | 49.5000 | AID1017 |
| M17 leucyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 (µMol) | 22.8400 | 1.0000 | 27.8360 | 138.0800 | AID1619 |
| large T antigen | Betapolyomavirus macacae | IC50 (µMol) | 14.6900 | 0.1600 | 24.9724 | 100.0000 | AID1903 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| alkaline phosphatase, germ cell type preproprotein | Homo sapiens (human) | EC50 (µMol) | 999.0000 | 0.5500 | 33.7339 | 74.0000 | AID696 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||